Bio-Rad Laboratories and Axis-Shield have announced the US launch of Bio-Rad's Bioplex 2200 Anti-CCP test for the early detection of rheumatoid arthritis.
The assay, which runs on the Bioplex 2200 system, measures anti-CCP (anti-cyclic citrullinated peptide antibodies), a marker that has been shown to have high specificity in the diagnosis of rheumatoid arthritis.
The Bioplex 2200 Anti-CCP assay is based on Axis-Shield's anti-CCP technology and was launched in territories outside the US earlier in 2010.
The Bioplex 2200 system is a fully-automated, random-access multiplex testing system and provides clinical laboratories with the capability to rapidly process multiple individual tests that are traditionally processed separately.
The Bioplex 2200 system can conserve patient sample volume, consolidate workstations and simplify workflow.